8-KRegulation FDExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Regulation FD Disclosure (Jan 10, 2012)

Filed January 10, 2012For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 9, 2012, to disclose information presented at the J.P. Morgan Healthcare Conference. The primary purpose of this filing was to furnish a copy of the presentation given by CEO Leonard S. Schleifer, titled 'Building a Biopharmaceutical Growth Company.' This presentation likely provided investors with an update on the company's strategic direction, pipeline progress, and overall growth trajectory. While the specific details of the presentation are not within the 8-K itself (only that it was furnished as an exhibit), such events are critical for investors to gauge management's outlook, key development milestones, and potential future performance of Regeneron's drug candidates and commercial products.

Key Highlights

  • 1Regeneron Pharmaceuticals presented at the J.P. Morgan Healthcare Conference on January 9, 2012.
  • 2The presentation, titled 'Building a Biopharmaceutical Growth Company,' was delivered by CEO Leonard S. Schleifer.
  • 3The 8-K filing includes the presentation as an exhibit (Exhibit 99.1).
  • 4This filing serves as a Regulation FD disclosure, ensuring all investors have access to the information shared.
  • 5The content of the presentation likely focused on the company's growth strategy and business development.
  • 6Investors can access the presentation for insights into Regeneron's pipeline and corporate strategy in early 2012.

Frequently Asked Questions

The main purpose of this 8-K filing is to furnish the presentation made by Regeneron's CEO at the J.P. Morgan Healthcare Conference as a public disclosure under Regulation FD. This ensures that all investors have access to the information presented.

The details of the corporate update are contained within the presentation titled 'Building a Biopharmaceutical Growth Company,' which is furnished as Exhibit 99.1 to this Form 8-K filing.

Based on the title 'Building a Biopharmaceutical Growth Company' and the context of the J.P. Morgan Healthcare Conference, the presentation likely covered Regeneron's business strategy, progress in its drug development pipeline, financial highlights, and its outlook for future growth.

This filing is not related to a specific material event or financial update in the traditional sense. It is a disclosure of information presented at a widely attended industry conference, intended to keep investors informed about the company's overall strategy and progress.